The PS methodology adjusted for ≥ 105 covariates, including baseline insulin and diabetes medication use and common comorbidities associated with diabetes and healthcare utilization, which may all be considered proxies for potential confounders, such as diabetes severity and duration that were not included in the registers (except for Sweden). The gene discussed is INS; the disease is diabetes mellitus.